Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18235336 | 0.88 | KIF11 (0.35) | KIF11ALOX5PTGS1PTGS2CA2 | |
| SCHEMBL805458 | 0.86 | LATS1 (0.40) | KIF11ALOX5PTGS1PTGS2ALDH1A1 | |
| SCHEMBL18235334 | 0.86 | KIF11 (0.34) | KIF11ALOX5PTGS1PTGS2CA2 | |
| SCHEMBL12341054 | 0.86 | LATS1 (0.40) | KIF11ALOX5PTGS1PTGS2ALDH1A1 | |
| SCHEMBL16167559 | 0.86 | KIF11 (0.34) | KIF11ALOX5PTGS1PTGS2ALDH1A1 | |
| SCHEMBL14868405 | 0.83 | ALDH1A1 (0.48) | KIF11ALOX5PTGS1PTGS2CA2 | |
| SCHEMBL13412862 | 0.83 | ALOX5 (0.36) | KIF11ALOX5PTGS1PTGS2CA2 | |
| SCHEMBL22428716 | 0.82 | ALOX5 (0.36) | KIF11ALOX5PTGS1PTGS2CA2 | |
| SCHEMBL20576799 | 0.82 | KIF11 (0.38) | KIF11ALOX5PTGS1PTGS2ALDH1A1 | |
| SCHEMBL19367955 | 0.81 | ALOX5 (0.32) | KIF11ALOX5PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112094300-A | Dicyano tetra-tert-butyl pyridine ruthenium metal organic compound, preparation method and application thereof | 荆楚理工学院 | 2020-12-18 | — | — | CN | claimed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240217979-A1 | GluN2 Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240217979-A1 | GluN2 Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-12016903-B2 | Long-acting growth hormone treatment | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-7288553-B2 | Indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| US-7282507-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-16 | — | — | US | disclosed |
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070117770-A1 | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof | CYLENE PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070032652-A1 | Methods of preparing quinolone analogs | SENHWA BIOSCIENCES, INC. (TW) | 2007-02-08 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | KIF11 3382/4885ALOX5 4680/4885PTGS1 2780/4885 |
| US-12016903-B2 | Long-acting growth hormone treatment | GHRHR, GHSR, GHITM | KIF11 768/4885ALOX5 2559/4885PTGS1 1109/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | KIF11 2992/4885ALOX5 3968/4885PTGS1 1457/4885 |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | P2RY1, P2RY11, UTS2R | KIF11 4024/4885ALOX5 2205/4885PTGS1 391/4885 |
| US-20240217979-A1 | GluN2 Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptors | GRIN2B, GRIN2A, GRIN2C | KIF11 4311/4885ALOX5 2397/4885PTGS1 458/4885 |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | TP53, CCNY, ACIN1 | KIF11 2710/4885ALOX5 727/4885PTGS1 2017/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | KIF11 3686/4885ALOX5 4773/4885PTGS1 3614/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | KIF11 3959/4885ALOX5 2816/4885PTGS1 3918/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | KIF11 3626/4885ALOX5 2130/4885PTGS1 900/4885 |
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | KIF11 3070/4885ALOX5 2882/4885PTGS1 2942/4885 |
| US-20070032652-A1 | Methods of preparing quinolone analogs | BAX, BAD, MCL1 | KIF11 2870/4885ALOX5 793/4885PTGS1 1065/4885 |
| US-11827609-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | KIF11 4475/4885ALOX5 1375/4885PTGS1 211/4885 |
| US-20070117770-A1 | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof | NOP2, POLRMT, FBL | KIF11 2481/4885ALOX5 4719/4885PTGS1 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.